Rockwell Medical Technologies (RMTI) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Rockwell Medical Reports Second Quarter 2015 Results
August 4, 2015 4:01 PM EDTWIXOM, Mich., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the second quarter of 2015.
Q2 2015 Financial Highlights
Sales were $13.0 million, in line with Q2 2014. Gross profit was $2.1 million, a 2.3% increase over Q2 2014. Gross profit margins increased to 15.9% compared to 15.5% in Q2 2014. R&D expense was $0.9 million compared to $0.8 million in Q1 2015.... More